Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
BioMAdvanced Diagnostics logo — Disrupting the Field of Biomarkers

BioMAdvanced Diagnostics

Disrupting the Field of Biomarkers

Founded 2021 France France 12 employees Venture round Total: $3.10M Medical Devices

General Information

Company Name BioMAdvanced Diagnostics
Founded Year 2021
Location France France
Employees 12
Industries Medical Devices
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with BioMAdvanced Diagnostics. To contact BioMAdvanced Diagnostics, visit biomadvanced-diagnostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioMAdvanced Diagnostics compare?

A PDF of BioMAdvanced Diagnostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioMAdvanced Diagnostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioMAdvanced Diagnostics

BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, France, established in 2021 as a spinoff from CR2TI and the University Hospital of Nantes. The company's disruptive approach in the field of biomarkers, stemming from 20 years of translational research, aims to revolutionize personalized medicine, enhancing patient outcomes and reducing risks through minimally invasive solutions. These efforts are anticipated to yield substantial cost reductions for health systems. BioMAdvanced Diagnostics' initial focus revolves around enhancing the follow-up care for kidney and lung transplant patients. Through the identification of biomarkers, this start-up facilitates the evaluation, prediction, and diagnosis of transplant rejection, thereby enabling tailored treatment and minimizing adverse effects. The company’s tests promise predictive scores and seamless integration into diagnostic and standard treatment protocols, designed for user-friendly implementation by medical practitioners. In addition, BioMAdvanced Diagnostics has received incubation support from Atlanpole and backing from SATT Ouest Valorisation. Notably, in September 2023, the company announced its 2nd round of seed investment, raising an additional 1.4 million euros, with contributions from Bpifrance, SODERO GESTION, and Pays de la Loire Participations. Moreover, as of February 2024, BioMAdvanced Diagnostics has secured ISO 13485 certification by BSI (certificate number MD 775018). This certification signifies compliance with the quality management system for medical devices, bolstering the company's credibility and market readiness.

Business keywords: MedTech, Biomarkers, Personalized Medicine, Transplantation, Healthcare Innovation, Translational Research, Clinical Diagnostics, Incubation, Seed Investment, ISO 13485 Certification

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €1.40M 3
Bpifrance SODERO GESTION Pays de la Loire Participations
Bpifrance, SODERO GESTION +1
14 Jul 2023
Seed Round €1.70M 4
Bpifrance SODERO GESTION Pays de la Loire Participations
Bpifrance, SODERO GESTION +2
27 Sep 2022

BioMAdvanced Diagnostics Alternatives & Competitors

BioMAdvanced Diagnostics vs
Predict4Health
Predict4Health France

AI-powered Precision Medicine for Organ Failure

Grant
24 employees
AI, Digital Health
BioMAdvanced Diagnostics vs
EDX Medical Group
EDX Medical Group United Kingdom

Developing innovative diagnostics to enable personalised treatment for cancer, heart disease and inf...

Seed
12 employees
Health Care, Medical Devices
BioMAdvanced Diagnostics vs
Coridea
Coridea United States

Global Medical Device Incubator with specialty in Cardiac, Pulmonary, and Renal Innovation

Debt Financing
10 employees
Health Care, Medical Devices

FAQ About BioMAdvanced Diagnostics

Disrupting the Field of Biomarkers
BioMAdvanced Diagnostics was founded in 2021.
BioMAdvanced Diagnostics is headquartered in France.
BioMAdvanced Diagnostics operates in Medical Devices. Its work centres on MedTech, Biomarkers, Personalized Medicine and Transplantation.
BioMAdvanced Diagnostics has approximately 12 employees.
BioMAdvanced Diagnostics has completed 2 funding rounds, raising a total of $3.10M. The latest funding stage is Venture round.
Top alternatives and competitors to BioMAdvanced Diagnostics include Predict4Health, EDX Medical Group, Coridea, moveUP - digital therapies, Cyted Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioMAdvanced Diagnostics and Predict4Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioMAdvanced Diagnostics, https://bouncewatch.com/company/biomadvanced-diagnostics, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes